Eisai Inc (Teaneck, NJ) recently announced that it has assumed US distribution responsibilities for Aciphex (rabeprazole sodium) from Janssen Pharmaceutica Inc affiliate JOM Pharmaceutical Services. Eisai and Janssen will continue to co-promote Aciphex, a proton pump inhibitor prescribed for gastro-esophageal reflux disease (GERD). Eisai is fulfilling purchase orders for Aciphex from a contract distribution center in Memphis, Tenn.The product is indicated for the treatment of symptomatic GERD, healing of erosive GERD, and maintenance of healed erosive GERD. Aciphex also is approved as part of the first 7-day treatment for Helicobacter pylori infections, the single most common cause of peptic ulcers. For more information, visit www.aciphex.com, or call 888-4ACIPHEX (888-422-4743).
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs